Novartis to Petition U.S. Supreme Court to Uphold Gilenya Patent
Novartis said it will petition the U.S. Supreme Court to uphold a patent that protects the dosing regimen of Gilenya (fingolimod) that’s approved…
FDA puts brakes on Sanofi’s $3.7B multiple sclerosis bet, imposing partial hold, over liver injuries
The $3.7 billion centerpiece of Paul Hudson’s R&D strategy for Sanofi has hit a setback. Seeing cases of drug-induced…
Stuart Schlossman
Welcome to the MSAA Ultimate MS Treatment Guide – an online tool to help people with multiple sclerosis
August 2022 MSAA is proud to announce the launch of the Ultimate MS Treatment Guide (MStreatmentguide.org) – an online tool…
Stuart Schlossman
Rituximab Outperforms Tecfidera at Preventing Relapses in Phase 3 Trial
by Marisa Wexler, MS | July 15, 2022 Patients on rituximab MS treatment 5 times less likely to experience relapse…
Stuart Schlossman
Researchers Report Fewer Relapses in Multiple Sclerosis with Off-Label Drug (rituximab)
July 2022 …
Stuart Schlossman
DMT for Multiple Sclerosis Tied to Lower Risk for In-Hospital COVID-19 Mortality
Mortality among patients with multiple sclerosis (MS) hospitalized for COVID-19 was lower among patients taking disease-modifying therapy (DMT), according to…
Stuart Schlossman
A compass to MS Care Rural America – from Lynchburg, VA
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
Diroximel Fumarate for Relapsing MS: How Does It Affect Clinical Outcomes?
June 8, 2022 – Mary Stroka The most frequent AEs were flushing (32.3%), nasopharyngitis (24.6%), and MS relapse during treatment with…
Stuart Schlossman
Biogen Secures Tecfidera Patent in EU Until 2028
Biogen has secured a new patent in Europe covering the use of its oral therapy Tecfidera (dimethyl fumarate) for multiple sclerosis (MS) through 2028,…
Stuart Schlossman
An MS Journey – Understanding Aspects of Specialty Pharmacy, Step Therapy & more (renewed from Sept 2019)
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
